A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Stein, EM; Walter, RB; Erba, HP; Fathi, AT; Advani, AS; Lancet, JE; Ravandi, F; Kovacsovics, T; DeAngelo, DJ; Bixby, D; Faderl, S; Jillella, AP; Ho, PA; O'Meara, MM; Zhao, BT; Biddle-Snead, C; Stein, AS

Stein, EM (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.

BLOOD, 2018; 131 (4): 387

Abstract

Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody target......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索